Skip to main content
. 2012 Feb 17;7(2):e31259. doi: 10.1371/journal.pone.0031259

Figure 3. Overexpression of MCAK with clinical progression of prostate cancer.

Figure 3

MCAK-immunostained sections of castration-resistant adenocarcinoma (A), castration-resistant small cell carcinoma (B), and hormone-sensitive prostate carcinoma (C). D) Significantly increased labeling for the mitotic centromere-associated protein MCAK with progression to CRPC, indicated by asterisks.